Stryker Corporation $SYK Shares Purchased by B. Metzler seel. Sohn & Co. AG

Posted by Stanley Muller on Aug 21st, 2026

B. Metzler seel. Sohn & Co. AG raised its holdings in Stryker Corporation (NYSE:SYK – Free Report) by 121.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 175,636 shares of the medical technology company’s stock after purchasing an additional 96,281 shares during the quarter. B. Metzler seel. Sohn & Co. AG’s holdings in Stryker were worth $55,297,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Gables Capital Management Inc. purchased a new stake in shares of Stryker during the 2nd quarter worth $25,000. Kilter Group LLC purchased a new position in shares of Stryker in the 2nd quarter valued at about $25,000. Godfrey Financial Associates Inc. acquired a new stake in shares of Stryker in the fourth quarter valued at about $26,000. Sankala Group LLC purchased a new stake in Stryker during the fourth quarter worth about $26,000. Finally, United Financial Planning Group LLC purchased a new stake in Stryker during the third quarter worth about $27,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Price Performance

Shares of SYK traded up $3.39 during mid-day trading on Friday, reaching $331.09. 1,448,865 shares of the company’s stock were exchanged, compared to its average volume of 2,362,085. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $396.86. The company has a market cap of $127.00 billion, a price-to-earnings ratio of 34.31, a PEG ratio of 2.17 and a beta of 0.76. The company has a 50-day simple moving average of $326.64 and a two-hundred day simple moving average of $332.66.

Stryker (NYSE:SYK – Get Free Report) last posted its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. The firm had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.Stryker’s revenue was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, sell-side analysts predict that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker’s dividend payout ratio is currently 36.48%.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on SYK shares. Citizens Jmp dropped their target price on shares of Stryker from $440.00 to $400.00 and set a “market outperform” rating for the company in a report on Monday, August 3rd. JPMorgan Chase & Co. decreased their price target on Stryker from $400.00 to $350.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st. Truist Financial raised their price objective on Stryker from $330.00 to $340.00 and gave the company a “hold” rating in a research note on Friday, July 31st. Royal Bank Of Canada decreased their target price on Stryker from $435.00 to $420.00 and set an “outperform” rating on the stock in a research report on Friday, July 31st. Finally, Evercore set a $350.00 target price on Stryker in a report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $386.28.

Get Our Latest Stock Analysis on SYK

More Stryker News

Here are the key news stories impacting Stryker this week:

Positive Sentiment: Wall Street remains broadly constructive on Stryker. Analysts maintain a consensus “Moderate Buy” rating and an average price target of $386.28, implying meaningful upside from recent levels. Although several firms lowered their targets, most retained Buy or Outperform ratings. Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
Positive Sentiment: Stryker’s latest quarterly results exceeded expectations: adjusted earnings were $3.69 per share versus a $3.49 consensus estimate, while revenue reached $6.59 billion against expectations of $6.58 billion. Revenue grew 9.4% year over year, and management maintained fiscal 2026 earnings guidance of $14.95–$15.10 per share.
Positive Sentiment: Institutional ownership remains substantial at 77.09%, with major investors including Norges Bank, Bank of America and Legal & General recently establishing or expanding positions. This may help support the stock over the longer term.
Neutral Sentiment: The company declared a quarterly dividend of $0.88 per share, equivalent to $3.52 annually and a yield of approximately 1.1%. The payout provides income support but is unlikely to be a major near-term catalyst.
Negative Sentiment: Director Ronda Stryker sold 300,000 shares for approximately $100.8 million on August 18 and another 50,000 shares for approximately $17.0 million on August 19. The transactions reduced her direct ownership, potentially raising concerns about insider confidence even though she still owns roughly 2.25 million shares. Stryker Director Sells 50,000 Shares of Stock
Negative Sentiment: Recent commentary characterizes Stryker’s sell-off as a potentially better entry point but notes that the latest quarter was not flawless. In addition, several analysts have trimmed price targets, suggesting expectations have moderated despite the overall bullish rating.

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 50,000 shares of the business’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total value of $17,005,000.00. Following the completion of the transaction, the director owned 2,251,375 shares of the company’s stock, valued at approximately $765,692,637.50. The trade was a 2.17% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Debra King sold 826 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the transaction, the insider owned 6,210 shares in the company, valued at approximately $2,088,423. This trade represents a 11.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 665,370 shares of company stock valued at $216,238,501 over the last quarter. Insiders own 4.60% of the company’s stock.

About Stryker

(Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.